307 / 1068
HPV associated Anal Cancer is genetically
distinct
•
Meulendijks et al ( 2015 )
•
138 anal SCC
No. % p53
I/C +
% p53
disruptive
3 yr loco-regional
control
3yr OS
mutations
HPV+ p16+ 93 10%
(9/93)
6 %
(1/18)
82 %
87 %
HPV- p16+ 4
33 %
(1/3)
75 %
75 %
HPV- p16- 10 50%
(5/10)
80 %
(8/10)
15 %
35 %
No difference in T or N stage between HPV+ and HPV - cancers